Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2018 04:00 ET | Source: AC Immune SA

AC Immune to Present at the Jefferies 2018 London Healthcare Conference

Lausanne, Switzerland, November 12, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...
November 09, 2018 04:00 ET | Source: AC Immune SA

AC Immune Shares Insights from Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and Other Misfolded Proteins in AD and Neurodegenerative Diseases

Increasing evidence points to Abeta oligomers as the toxic species in AD, and likely linked to Tau pathology and neuroinflammation. Immunotherapies and small molecule anti-Tau therapeutics hold...
November 01, 2018 06:00 ET | Source: AC Immune SA

AC Immune to Present at 2018 Society for Neurosciences Meeting

Update on Therapeutic and Diagnostic Programs Targeting TDP-43 Lausanne, Switzerland, November 1, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company...
November 01, 2018 05:00 ET | Source: AC Immune SA

AC Immune to Host Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and the Involvement of Other Misfolded Proteins in AD and Neurodegenerative Diseases

Key Opinion Leaders to discuss emerging concepts in the development of therapies for Alzheimer's Disease and other neurodegenerative diseasesMeeting scheduled for November 5, 2018, from 12:00pm...
October 29, 2018 06:00 ET | Source: AC Immune SA

AC Immune Partner Life Molecular Imaging Presents New Clinical Study Results for Tau PET-Tracer 18F-PI-2620

Study confirms the good performance of tau PET-tracer 18F-PI-2620 in detecting and quantifying tau deposition, a key pathological feature of Alzheimer's disease Results presented at the 11th...
October 29, 2018 05:00 ET | Source: AC Immune SA

AC Immune SA: New Data Supporting Crenezumab as Potential Alzheimer's Therapy

Studies show that crenezumab protects neurons from Alzheimer's disease pathologies in vitro and further support the clinical rationale for crenezumab as a potential treatment for Alzheimer's...
October 25, 2018 04:00 ET | Source: AC Immune SA

AC Immune Selected to Present Progress on its Tau Morphomer Program in the Late Breaking News Session at CTAD Conference in Barcelona

Lausanne, Switzerland, October 25, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases has...
October 22, 2018 04:00 ET | Source: AC Immune SA

AC Immune Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence

Lausanne, Switzerland, October 22, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...
August 20, 2018 04:00 ET | Source: AC Immune SA

AC Immune Announces Important Clinical Milestones for ACI-24 Vaccine in Alzheimer's Disease and Down Syndrome

Start of Phase 2 trial with ACI-24 in patients with mild Alzheimer's disease; first patient enrolled Recruitment completed for high-dose cohort of Phase 1b study with ACI-24 for Abeta-related...
August 08, 2018 04:00 ET | Source: AC Immune SA

AC Immune Reports Second Quarter 2018 Financial Results and Corporate Update

New total cash position of approximately CHF 210 million that is expected to extend cash runway to Q3 2021, excluding potential incoming milestones Financial position strengthened after Q2 close...